Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [07.11.2019] – [Helping a physician to become comfortable with the MP] sallieqhome:starting:physician:reluctant [07.19.2019] – [Specific research] sallieq
Line 190: Line 190:
  
  
-Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}})) PMID 24772521+Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{pubmed>long:24772521}}))  //  Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//
  
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.